(The Hill) — Drugmaker AstraZeneca will cap out-of-pocket costs at $35 for all its inhaler products, the company announced Monday. The cap is effective June 1 and will apply to the company’s entire ...

The future of AstraZeneca’s three-in-one inhaler Breztri, which was previously hit with a surprising FDA rejection, was hinging on the outcome of another phase 3 trial. And the results from that trial ...

copd-pulmonology-xray-ca0416 The FDA has approved Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate; AstraZeneca) for the maintenance treatment of ...

Breztri can cost around $400 without insurance. Medicare drug plans may cover inhalers for COPD, including drugs like Breztri, but specific coverage and cost depend on the exact plan. Breztri ...

Breztri can cost $400 or more without insurance, but Medicare may cover inhaler drugs for COPD, including Breztri. That said, the specific coverage and costs vary based on your exact plan. Breztri ...

AstraZeneca and GlaxoSmithKline have long locked horns in their battle for respiratory supremacy with the latter holding the clear advantage in triple-drug inhaler market. Can another round of ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. (The Hill) — Drugmaker AstraZeneca will cap ...

(The Hill) — Drugmaker AstraZeneca will cap out-of-pocket costs at $35 for all its inhaler products, the company announced Monday. Get Hawaii’s latest morning news delivered to your inbox, sign up for ...